NCT05813132 is a NA clinical trial of BEAM Protocol in Lymphoma, sponsored by Rehab Werida.

Who is sponsoring NCT05813132?

NCT05813132 is sponsored by Rehab Werida.

What drugs are being tested in NCT05813132?

Interventions in NCT05813132: BEAM Protocol, CEM protocol.

Is NCT05813132 still recruiting?

NCT05813132 is currently completed. Last updated 5 September 2024.

Last reviewed 2024-09-05 · How we verify

NCT05813132

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Completed NA Last updated 5 September 2024

What this trial tests

NA trial testing BEAM Protocol in Lymphoma in 58 participants. Completed in 30 December 2023.

Timeline

11 November 2022

Primary endpoint
30 December 2023

30 December 2023

Quick facts

Lead sponsor	Rehab Werida
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	11 November 2022
Primary completion	30 December 2023
Estimated completion	30 December 2023
Sites	1 location across Egypt

Drugs / interventions tested

BEAM Protocol — full drug profile →
CEM protocol — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Rehab Werida — full company profile →

Who can join

Adults 18 to 70, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning regimen in lymphoma patients in safety profile\& toxicity, infections (Febrile neutropenia) during transplant, time to engraftment (recovery not neutropenic), Length of stay at hospital, time to relapse, and other complications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
Eltelbanei MA, El-Bassiouny NA, Abdalla MS, Khalaf M, et al · · 2024 · cited 1× · PMID 39134959 · DOI 10.1186/s12885-024-12694-9

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Rehab Werida trials

Trials by the same sponsor.

NCT07379788 — ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling · recruiting
NCT05459701 — Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD) · Phase 4 · completed
NCT05459389 — Early Targeted Antibiotic Therapy in Patients With Sepsis · NA · completed
NCT05291039 — Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. · NA · completed
NCT05291338 — Pharmacogenetic Study in Hepatocellular Carcinoma Patients. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05813132 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rehab Werida
Last refreshed: 5 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05813132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing